tirzepatide no longer shortage GLP-1 on FDA's Drug List The recent announcement that Tirzepatide

This case study , published in 2023, describes three female patients taking semaglutide who visited their healthcare clinic due to severe mouth dryness, as well as minimal frothy saliva. After underlying medical problems were excluded (such as low water intake or a condition called Sjogrens disease) as the cause, the females were diagnosed with hyposalivation (dry mouth)

Switching was assessed from prescription sequences reconstructed using drug-name fields and their corresponding service dates

Also, early adoption of novel therapies contributed to the dominance

It was conducted to assess the effect of oral semaglutide versus placebo, when added to standard of care, on cardiovascular outcomes in people with type 2 diabetes who are at high risk of MACE (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke)